Nick Waldron
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nick Waldron has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Adam Sharp
Institute of Cancer Research 6 , Royal Marsden NHS Foundation Trust, London, United Kingdom
11 shared publications - Alec Paschalis
The Institute for Cancer Research, London, United Kingdom
10 shared publications - Ana Ferreira
The Institute of Cancer Research, London, United Kingdom
10 shared publications - Andrea Biondo
Drug Development Unit, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
10 shared publications - Andrew J. Martin
Department of Cellular Pathology, St George’s Hospital, London, United Kingdom
10 shared publications - Anna Minchom
Drug Development Unit, Royal Marsden/Institute of Cancer Research, Sutton, UK
10 shared publications
Latest Publications
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4. from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
Supplementary Figure 4. from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4. from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
Supplementary Figure 4. from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1-2. from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
Supplementary Figure 1-2. from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1-2. from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
Supplementary Figure 1-2. from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5. from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
Supplementary Figure 5. from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5. from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
Supplementary Figure 5. from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
Supplementary Figure 3 from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
Supplementary Figure 3 from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Data from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
Purpose:Activation of the phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling pathway promotes tumor immune evasion by suppressing effector T-cell infiltration and enhancing regulatory T-cell (Treg) activity, contributing to resistance to immune checkpoint inhibitors (ICI). Preclinical studies have demonstrated that inhibition of this pathway can restore antitumor immunity and synergize with PD-1/PD-L1 blockade. We explore the synergistic clinical potential of targeting the PI3K/AKT pathway in combination with atezolizumab to overcome immunotherapy resistance in recurrent glioblastoma (GBM) and advanced solid tumors. Patients and Methods:Phase Ib, investigator-initiated, open-label study (NCT03673787) composed of a proof-of-concept dose escalation part A of ipatasertib plus atezolizumab in a 3 + 3 design. Adult patients with treatment-refractory advanced cancers were enrolled into cohort A1 and recurrent GBM into cohort A2. Part B enrolled patients into six exploratory cohorts. The study aims to evaluate the safety, immune-modulatory effects, and preliminary efficacy of the combination of ipatasertib with atezolizumab. Results:The combination was well tolerated, with no dose-limiting toxicities at the recommended phase II dose of ipatasertib 400 mg daily plus atezolizumab 1,200 mg every 3 weeks. Pharmacodynamic analysis demonstrated depletion of FOXP3+ Tregs and increased infiltration of CD8+ effector T cells within the tumor microenvironment (TME). Durable exceptional responses were seen in some patients with treatment-refractory or recurrent GBM. Conclusions:This is the first report in clinical samples showing that ipatasertib efficiently depletes FOXP3+ Tregs and results in increased infiltration of effector CD8+ T cells in the TME. This was associated with preliminary efficacy in a subset of patients with treatment-refractory GBM.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
Purpose:Activation of the phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling pathway promotes tumor immune evasion by suppressing effector T-cell infiltration and enhancing regulatory T-cell (Treg) activity, contributing to resistance to immune checkpoint inhibitors (ICI). Preclinical studies have demonstrated that inhibition of this pathway can restore antitumor immunity and synergize with PD-1/PD-L1 blockade. We explore the synergistic clinical potential of targeting the PI3K/AKT pathway in combination with atezolizumab to overcome immunotherapy resistance in recurrent glioblastoma (GBM) and advanced solid tumors. Patients and Methods:Phase Ib, investigator-initiated, open-label study (NCT03673787) composed of a proof-of-concept dose escalation part A of ipatasertib plus atezolizumab in a 3 + 3 design. Adult patients with treatment-refractory advanced cancers were enrolled into cohort A1 and recurrent GBM into cohort A2. Part B enrolled patients into six exploratory cohorts. The study aims to evaluate the safety, immune-modulatory effects, and preliminary efficacy of the combination of ipatasertib with atezolizumab. Results:The combination was well tolerated, with no dose-limiting toxicities at the recommended phase II dose of ipatasertib 400 mg daily plus atezolizumab 1,200 mg every 3 weeks. Pharmacodynamic analysis demonstrated depletion of FOXP3+ Tregs and increased infiltration of CD8+ effector T cells within the tumor microenvironment (TME). Durable exceptional responses were seen in some patients with treatment-refractory or recurrent GBM. Conclusions:This is the first report in clinical samples showing that ipatasertib efficiently depletes FOXP3+ Tregs and results in increased infiltration of effector CD8+ T cells in the TME. This was associated with preliminary efficacy in a subset of patients with treatment-refractory GBM.
- Open Access
- 12 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (15) , OF1-OF16
Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
Purpose: Activation of the phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling pathway promotes tumor immune evasion by suppressing effector T-cell infiltration and enhancing regulatory T-cell (Treg) activity, contributing to resistance to immune checkpoint inhibitors (ICI). Preclinical studies have demonstrated that inhibition of this pathway can restore antitumor immunity and synergize with PD-1/PD-L1 blockade. We explore the synergistic clinical potential of targeting the PI3K/AKT pathway in combination with atezolizumab to overcome immunotherapy resistance in recurrent glioblastoma (GBM) and advanced solid tumors. Patients and Methods: Phase Ib, investigator-initiated, open-label study (NCT03673787) composed of a proof-of-concept dose escalation part A of ipatasertib plus atezolizumab in a 3 + 3 design. Adult patients with treatment-refractory advanced cancers were enrolled into cohort A1 and recurrent GBM into cohort A2. Part B enrolled patients into six exploratory cohorts. The study aims to evaluate the safety, immune-modulatory effects, and preliminary efficacy of the combination of ipatasertib with atezolizumab. Results: The combination was well tolerated, with no dose-limiting toxicities at the recommended phase II dose of ipatasertib 400 mg daily plus atezolizumab 1,200 mg every 3 weeks. Pharmacodynamic analysis demonstrated depletion of FOXP3+ Tregs and increased infiltration of CD8+ effector T cells within the tumor microenvironment (TME). Durable exceptional responses were seen in some patients with treatment-refractory or recurrent GBM. Conclusions: This is the first report in clinical samples showing that ipatasertib efficiently depletes FOXP3+ Tregs and results in increased infiltration of effector CD8+ T cells in the TME. This was associated with preliminary efficacy in a subset of patients with treatment-refractory GBM.
- 12 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (15) , OF1-OF16
Open AccessPhase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
Purpose: Activation of the phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling pathway promotes tumor immune evasion by suppressing effector T-cell infiltration and enhancing regulatory T-cell (Treg) activity, contributing to resistance to immune checkpoint inhibitors (ICI). Preclinical studies have demonstrated that inhibition of this pathway can restore antitumor immunity and synergize with PD-1/PD-L1 blockade. We explore the synergistic clinical potential of targeting the PI3K/AKT pathway in combination with atezolizumab to overcome immunotherapy resistance in recurrent glioblastoma (GBM) and advanced solid tumors. Patients and Methods: Phase Ib, investigator-initiated, open-label study (NCT03673787) composed of a proof-of-concept dose escalation part A of ipatasertib plus atezolizumab in a 3 + 3 design. Adult patients with treatment-refractory advanced cancers were enrolled into cohort A1 and recurrent GBM into cohort A2. Part B enrolled patients into six exploratory cohorts. The study aims to evaluate the safety, immune-modulatory effects, and preliminary efficacy of the combination of ipatasertib with atezolizumab. Results: The combination was well tolerated, with no dose-limiting toxicities at the recommended phase II dose of ipatasertib 400 mg daily plus atezolizumab 1,200 mg every 3 weeks. Pharmacodynamic analysis demonstrated depletion of FOXP3+ Tregs and increased infiltration of CD8+ effector T cells within the tumor microenvironment (TME). Durable exceptional responses were seen in some patients with treatment-refractory or recurrent GBM. Conclusions: This is the first report in clinical samples showing that ipatasertib efficiently depletes FOXP3+ Tregs and results in increased infiltration of effector CD8+ T cells in the TME. This was associated with preliminary efficacy in a subset of patients with treatment-refractory GBM.